Tesmilifene

DB04905

small molecule investigational

Deskripsi

Tesmilifene is a novel potentiator of chemotherapy which, when added to doxorubicin, achieved an unexpected and very large survival advantage over doxorubicin alone in a randomized trial in advanced breast cancer.

Struktur Molekul 2D

Berat 283.4079
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Hepatic

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

937 Data
Apixaban The risk or severity of adverse effects can be increased when Tesmilifene is combined with Apixaban.
Dasatinib Dasatinib may increase the anticoagulant activities of Tesmilifene.
Ursodeoxycholic acid The risk or severity of adverse effects can be increased when Tesmilifene is combined with Ursodeoxycholic acid.
Glycochenodeoxycholic Acid The risk or severity of adverse effects can be increased when Tesmilifene is combined with Glycochenodeoxycholic Acid.
Cholic Acid The risk or severity of adverse effects can be increased when Tesmilifene is combined with Cholic Acid.
Glycocholic acid The risk or severity of adverse effects can be increased when Tesmilifene is combined with Glycocholic acid.
Deoxycholic acid The risk or severity of adverse effects can be increased when Tesmilifene is combined with Deoxycholic acid.
Taurocholic acid The risk or severity of adverse effects can be increased when Tesmilifene is combined with Taurocholic acid.
Obeticholic acid The risk or severity of adverse effects can be increased when Tesmilifene is combined with Obeticholic acid.
Chenodeoxycholic acid The risk or severity of adverse effects can be increased when Tesmilifene is combined with Chenodeoxycholic acid.
Taurochenodeoxycholic acid The risk or severity of adverse effects can be increased when Tesmilifene is combined with Taurochenodeoxycholic acid.
Tauroursodeoxycholic acid The risk or severity of adverse effects can be increased when Tesmilifene is combined with Tauroursodeoxycholic acid.
Bamet-UD2 The risk or severity of adverse effects can be increased when Tesmilifene is combined with Bamet-UD2.
Dehydrocholic acid The risk or severity of adverse effects can be increased when Tesmilifene is combined with Dehydrocholic acid.
Hyodeoxycholic Acid The risk or severity of adverse effects can be increased when Tesmilifene is combined with Hyodeoxycholic Acid.
Glucosamine Glucosamine may increase the antiplatelet activities of Tesmilifene.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Tesmilifene is combined with Ibritumomab tiuxetan.
Obinutuzumab The risk or severity of adverse effects can be increased when Tesmilifene is combined with Obinutuzumab.
Pentoxifylline Pentoxifylline may increase the antiplatelet activities of Tesmilifene.
Rivaroxaban Tesmilifene may increase the anticoagulant activities of Rivaroxaban.
Tipranavir Tipranavir may increase the antiplatelet activities of Tesmilifene.
Urokinase Tesmilifene may increase the anticoagulant activities of Urokinase.
Vitamin E Vitamin E may increase the antiplatelet activities of Tesmilifene.
Aripiprazole The metabolism of Aripiprazole can be increased when combined with Tesmilifene.
Aripiprazole lauroxil The metabolism of Aripiprazole lauroxil can be increased when combined with Tesmilifene.
Eliglustat The metabolism of Eliglustat can be decreased when combined with Tesmilifene.
Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Tesmilifene.
Cilostazol The metabolism of Cilostazol can be decreased when combined with Tesmilifene.
Colchicine The metabolism of Colchicine can be decreased when combined with Tesmilifene.
Iloperidone The metabolism of Iloperidone can be decreased when combined with Tesmilifene.
Retapamulin The metabolism of Retapamulin can be decreased when combined with Tesmilifene.
Tofacitinib The metabolism of Tofacitinib can be decreased when combined with Tesmilifene.
Vardenafil The metabolism of Vardenafil can be decreased when combined with Tesmilifene.
Zopiclone The metabolism of Zopiclone can be decreased when combined with Tesmilifene.
Lovastatin The metabolism of Lovastatin can be decreased when combined with Tesmilifene.
Alfuzosin The metabolism of Alfuzosin can be decreased when combined with Tesmilifene.
Alprazolam The metabolism of Alprazolam can be decreased when combined with Tesmilifene.
Ifosfamide The metabolism of Ifosfamide can be increased when combined with Tesmilifene.
Perampanel The metabolism of Perampanel can be increased when combined with Tesmilifene.
Warfarin The serum concentration of Warfarin can be increased when it is combined with Tesmilifene.
Acenocoumarol The serum concentration of Acenocoumarol can be increased when it is combined with Tesmilifene.
(R)-warfarin The serum concentration of (R)-warfarin can be increased when it is combined with Tesmilifene.
R,S-Warfarin alcohol The serum concentration of R,S-Warfarin alcohol can be increased when it is combined with Tesmilifene.
S,R-Warfarin alcohol The serum concentration of S,R-Warfarin alcohol can be increased when it is combined with Tesmilifene.
(S)-Warfarin The serum concentration of (S)-Warfarin can be increased when it is combined with Tesmilifene.
Midazolam The serum concentration of Midazolam can be increased when it is combined with Tesmilifene.
Tacrolimus The serum concentration of Tacrolimus can be increased when it is combined with Tesmilifene.
Atorvastatin The metabolism of Atorvastatin can be decreased when combined with Tesmilifene.
Mirabegron The serum concentration of Tesmilifene can be increased when it is combined with Mirabegron.
Pentosan polysulfate The risk or severity of adverse effects can be increased when Pentosan polysulfate is combined with Tesmilifene.
Limaprost Limaprost may increase the antiplatelet activities of Tesmilifene.
Omega-3 fatty acids Omega-3 fatty acids may increase the antiplatelet activities of Tesmilifene.
Tositumomab The risk or severity of adverse effects can be increased when Tesmilifene is combined with Tositumomab.
Erlotinib The serum concentration of Erlotinib can be decreased when it is combined with Tesmilifene.
Lepirudin The risk or severity of bleeding can be increased when Tesmilifene is combined with Lepirudin.
Bivalirudin The risk or severity of bleeding can be increased when Tesmilifene is combined with Bivalirudin.
Alteplase The risk or severity of bleeding can be increased when Tesmilifene is combined with Alteplase.
Reteplase The risk or severity of bleeding can be increased when Tesmilifene is combined with Reteplase.
Anistreplase The risk or severity of bleeding can be increased when Tesmilifene is combined with Anistreplase.
Tenecteplase The risk or severity of bleeding can be increased when Tesmilifene is combined with Tenecteplase.
Abciximab The risk or severity of bleeding can be increased when Tesmilifene is combined with Abciximab.
Drotrecogin alfa The risk or severity of bleeding can be increased when Tesmilifene is combined with Drotrecogin alfa.
Streptokinase The risk or severity of bleeding can be increased when Tesmilifene is combined with Streptokinase.
Dicoumarol The risk or severity of bleeding can be increased when Tesmilifene is combined with Dicoumarol.
Argatroban The risk or severity of bleeding can be increased when Tesmilifene is combined with Argatroban.
Ardeparin The risk or severity of bleeding can be increased when Tesmilifene is combined with Ardeparin.
Phenindione The risk or severity of bleeding can be increased when Tesmilifene is combined with Phenindione.
Fondaparinux The risk or severity of bleeding can be increased when Tesmilifene is combined with Fondaparinux.
Phenprocoumon The risk or severity of bleeding can be increased when Tesmilifene is combined with Phenprocoumon.
Dipyridamole The risk or severity of bleeding can be increased when Tesmilifene is combined with Dipyridamole.
Heparin The risk or severity of bleeding can be increased when Tesmilifene is combined with Heparin.
Enoxaparin The risk or severity of bleeding can be increased when Tesmilifene is combined with Enoxaparin.
Epoprostenol The risk or severity of bleeding can be increased when Tesmilifene is combined with Epoprostenol.
4-hydroxycoumarin The risk or severity of bleeding can be increased when Tesmilifene is combined with 4-hydroxycoumarin.
Coumarin The risk or severity of bleeding can be increased when Tesmilifene is combined with Coumarin.
Ximelagatran The risk or severity of bleeding can be increased when Tesmilifene is combined with Ximelagatran.
Desmoteplase The risk or severity of bleeding can be increased when Tesmilifene is combined with Desmoteplase.
Defibrotide The risk or severity of bleeding can be increased when Tesmilifene is combined with Defibrotide.
Ancrod The risk or severity of bleeding can be increased when Tesmilifene is combined with Ancrod.
Beraprost The risk or severity of bleeding can be increased when Tesmilifene is combined with Beraprost.
Prasugrel The risk or severity of bleeding can be increased when Tesmilifene is combined with Prasugrel.
Sulodexide The risk or severity of bleeding can be increased when Tesmilifene is combined with Sulodexide.
Semuloparin The risk or severity of bleeding can be increased when Tesmilifene is combined with Semuloparin.
Idraparinux The risk or severity of bleeding can be increased when Tesmilifene is combined with Idraparinux.
Cangrelor The risk or severity of bleeding can be increased when Tesmilifene is combined with Cangrelor.
Astaxanthin The risk or severity of bleeding can be increased when Tesmilifene is combined with Astaxanthin.
Otamixaban The risk or severity of bleeding can be increased when Tesmilifene is combined with Otamixaban.
Amediplase The risk or severity of bleeding can be increased when Tesmilifene is combined with Amediplase.
Danaparoid The risk or severity of bleeding can be increased when Tesmilifene is combined with Danaparoid.
Dalteparin The risk or severity of bleeding can be increased when Tesmilifene is combined with Dalteparin.
Tinzaparin The risk or severity of bleeding can be increased when Tesmilifene is combined with Tinzaparin.
Ethyl biscoumacetate The risk or severity of bleeding can be increased when Tesmilifene is combined with Ethyl biscoumacetate.
Nadroparin The risk or severity of bleeding can be increased when Tesmilifene is combined with Nadroparin.
Triflusal The risk or severity of bleeding can be increased when Tesmilifene is combined with Triflusal.
Ticagrelor The risk or severity of bleeding can be increased when Tesmilifene is combined with Ticagrelor.
Ditazole The risk or severity of bleeding can be increased when Tesmilifene is combined with Ditazole.
Vorapaxar The risk or severity of bleeding can be increased when Tesmilifene is combined with Vorapaxar.
Sodium citrate The risk or severity of bleeding can be increased when Tesmilifene is combined with Sodium citrate.
Dextran The risk or severity of bleeding can be increased when Tesmilifene is combined with Dextran.
Bemiparin The risk or severity of bleeding can be increased when Tesmilifene is combined with Bemiparin.

Target Protein

ATP-dependent translocase ABCB1 ABCB1
Histamine H1 receptor HRH1

Referensi & Sumber

Artikel (PubMed)
  • PMID: 16823511
    Liu J, Tu D, Dancey J, Reyno L, Pritchard KI, Pater J, Seymour LK: Quality of life analyses in a clinical trial of DPPE (tesmilifene) plus doxorubicin versus doxorubicin in patients with advanced or metastatic breast cancer: NCIC CTG Trial MA.19. Breast Cancer Res Treat. 2006 Dec;100(3):263-71. Epub 2006 Jul 6.
  • PMID: 16413681
    Vincent M: Tesmilifene may enhance breast cancer chemotherapy by killing a clone of aggressive, multi-drug resistant cells through its action on the p-glycoprotein pump. Med Hypotheses. 2006;66(4):715-31. Epub 2006 Jan 18.
  • PMID: 16217292
    Raghavan D, Brandes LJ, Klapp K, Snyder T, Styles E, Tsao-Wei D, Lieskovsky G, Quinn DI, Ramsey EW: Phase II trial of tesmilifene plus mitoxantrone and prednisone for hormone refractory prostate cancer: high subjective and objective response in patients with symptomatic metastases. J Urol. 2005 Nov;174(5):1808-13; discussion 1813.
  • PMID: 10755318
    Brandes LJ, Queen GM, LaBella FS: N,N-diethyl-2-4-(phenylmethyl)phenoxy ethanamine (DPPE) a chemopotentiating and cytoprotective agent in clinical trials: interaction with histamine at cytochrome P450 3A4 and other isozymes that metabolize antineoplastic drugs. Cancer Chemother Pharmacol. 2000;45(4):298-304.
  • PMID: 2374133
    Brandes LJ, Hogg GR: Study of the in-vivo antioestrogenic action of N,N-diethyl-2-4-(phenylmethyl)phenoxyethanamine HCl (DPPE), a novel intracellular histamine antagonist and antioestrogen binding site ligand. J Reprod Fertil. 1990 May;89(1):59-67.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul